Global pharmaceutical major Lupin Limited announced signing of an agreement to acquire all rights to two inhalation medicines, Brovana (arformoterol tartrate) inhalation solution and Xopenex HFA (levalbuterol tartrate) inhalation aerosol, from Sunovion Pharmaceuticals Inc. for a purchase price of US$ 75 million. Lupin expects the transaction to be accretive to earnings in the first year.
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the US and strengthens the company
